David Evans, a Managing Director in Alvarez & Marsal’s Transaction Advisory Group in London, recently spoke with Share Radio on the sharp rise in acquisition values of UK companies, while overall levels of M&A activity have fallen.
According to David, one very large transaction that closed in March 2016 influenced overall M&A activity statistics, but is not indicative of a general increase in inward acquisitions. In fact, the M&A volume metric demonstrates a slowdown in activity.
Additionally, David describes how the market has become more segmented and effected by changes in China’s economy and fluctuating oil prices. While there was a modest start to 2016, A&M has seen an increase in midmarket sell-side work in the last quarter, suggesting deal volumes may rebound in the second half of 2016.
To listen to the full discussion, click here.
Canada’s Private Capital Outlook 2026: Infrastructure, Insight, and Operational Alpha
May 19, 2026
Canadian private capital enters 2026 in a state of disciplined optimism. The environment is more selective, more data-driven, and significantly more execution-focused than in prior cycles.
Infrastructure Pulse Survey Report: Spring 2026, North America and Europe
May 14, 2026
The Infrastructure Pulse Survey Report for Spring 2026, published by Alvarez & Marsal in collaboration with the Global Infrastructure Investor Association (GIIA), offers an insight into how investors across North America and Europe are reading the current investment landscape through a period of macroeconomic and geopolitical uncertainty.
Alvarez & Marsal Continues to Strengthen Transaction Advisory Practice in Australia with Senior Talent
May 13, 2026
Alvarez & Marsal (A&M), a leading global professional services firm, today announced the appointment of Sydney-based Roshan Emmanuel as a Managing Director within its Global Transaction Advisory Group (Global TAG), underscoring the firm’s rapid growth and continued investment in the Australian market.
Carving Out Success: Life Sciences Companies Are Rationalizing Portfolios by Divesting Non-Core Assets
May 12, 2026
Historically, large healthcare and life sciences corporations have focused deal activity on a breadth of diverse assets. However, the landscape is undergoing significant transformation as businesses shift to rationalize their portfolios and invest in fewer core areas.
